[Comparison of the therapeutic results of bromocriptine treatment of prolactin microadenoma and macroadenoma].

26 infertile women with prolactinomas were treated by bromocriptine, 24 of them (92%) became pregnant. All of 11 cases with microadenoma restored fertility, 13 out of 15 patients with macroadenomas became fertile. The total is 32 pregnancies. 4 of 32 pregnancies developed spontaneous abortion or fetal death in uterus. In all the women with microadenomas and 11 cases with macroadenomas there were no symptom of enlargement of pituitary tumor, 2 patients with macroadenomas developed visual field defect or paralysis of left oculomotor nerves. 22 patients continued bromocriptine medication for 4.6 +/- 3.6 months and in 6 patients took bromocriptine until delivery. No congenital malformation were found, the development and intelligence were normal in their children. 4 women with microadenomas restored menses at postpartum without taking bromocriptine. The other patients still suffered amenorrhea and galactorrhea after delivery. 8 patients breast-feed their infants for 17.9 +/- 9.5 (7-33) months, no harmful effect on prolactinomas was found. Our data suggest: (1) The pregnancy rate in women with prolactinomas treated with bromocriptine was 92%. (2) Women with microprolactinomas who became pregnant appear to have a very low risk for developing complications and women with macroprolactinomas should be followed closely throughout pregnancy for pituitary tumors enlargement. (3) Bromocriptine therapy do not increase the risk of spontaneous abortion in women with prolactinoma and congenital anomalies of their offspring during pregnancy.